RU2016143921A - Композиция для применения в лечении или предупреждении вирусных или бактериальных инфекций у субъекта, проходящего противоопухолевую химиотерапию, лечение лейкоза или лечение СПИД, содержащая l.reuteri ler03 и/или l.salivarius ls06 - Google Patents
Композиция для применения в лечении или предупреждении вирусных или бактериальных инфекций у субъекта, проходящего противоопухолевую химиотерапию, лечение лейкоза или лечение СПИД, содержащая l.reuteri ler03 и/или l.salivarius ls06 Download PDFInfo
- Publication number
- RU2016143921A RU2016143921A RU2016143921A RU2016143921A RU2016143921A RU 2016143921 A RU2016143921 A RU 2016143921A RU 2016143921 A RU2016143921 A RU 2016143921A RU 2016143921 A RU2016143921 A RU 2016143921A RU 2016143921 A RU2016143921 A RU 2016143921A
- Authority
- RU
- Russia
- Prior art keywords
- dsm
- composition
- treatment
- bacterial strain
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (17)
1. Композиция для применения в качестве противовирусного и/или противобактериального агента у индивидуумов, проходящих противоопухолевое химиотерапевтическое лечение, лечение синдрома приобретенного иммунодефицита и лечение лейкозов, содержащая смесь, состоящую из:
штамма бактерий, принадлежащих виду Lactobacillus reuteri, идентифицированного как Lactobacillus reuteri LRE03, с депозитарным номером DSM 23879, депонированного 05.08.2010 Probiotical SpA в Немецкой коллекции микроорганизмов и клеточных культур (DSMZ GmbH), и/или
штамма бактерий, принадлежащих виду Lactobacillus salivarius, идентифицированного как Lactobacillus salivarius LS06, с депозитарным номером DSM 26037, депонированного 06.06.2012 Probiotical SpA в Немецкой коллекции микроорганизмов и клеточных культур (DSMZ GmbH).
2. Композиция для применения по п. 1, состоящая из смеси, дополнительно содержащей:
штамм бактерий, принадлежащих виду Lactobacillus fermentum, идентифицированный как Lactobacillus fermentum LF11, с депозитарным номером DSM 19188, депонированный 20.03.2007 Anidral S.r.l. Company (в настоящее время Probiotical S.p.A) в Немецкой коллекции микроорганизмов и клеточных культур (DSMZ GmbH).
3. Композиция для применения по п. 1 или 2, содержащая смесь с концентрацией бактерий от 1×108 колониеобразующих единиц (КОЕ)/г смеси до 1×1012 КОЕ/г смеси, предпочтительно от 1×109 КОЕ/г смеси до 1×1011 КОЕ/г смеси.
4. Композиция для применения по п. 3, где указанная смесь содержит или, альтернативно, состоит из:
штамма бактерий Lactobacillus reuteri LRE03 DSM 23879 и штамма бактерий Lactobacillus salivarius LS06 DSM 26037 в массовом соотношении от 1:5 до 5:1, предпочтительно от 1:3 до 3:1, еще более предпочтительно от 1:2 до 2:1 или 1:1, или
штамма бактерий Lactobacillus reuteri LRE03 DSM 23879 и штамма бактерий Lactobacillus fermentum LF11 DSM 19188 в массовом соотношении от 1:5 до 5:1, предпочтительно от 1:3 до 3:1, еще более предпочтительно от 1:2 до 2:1 или 1:1, или
штамма бактерий Lactobacillus salivarius LS06 DSM 26037 и штамма бактерий Lactobacillus fermentum LF11 DSM 19188 в массовом соотношении от 1:5 до 5:1, предпочтительно от 1:3 до 3:1, еще более предпочтительно от 1:2 до 2:1 или 1:1.
5. Композиция для применения по п. 3, где указанная смесь содержит или, альтернативно, состоит из:
штамма бактерий Lactobacillus reuteri LRE03 DSM 23879, штамма бактерий Lactobacillus salivarius LS06 DSM 26037 и штамма бактерий Lactobacillus fermentum LF11 DSM 19188, в массовом соотношении, выбранном из 3:2:1, 3:1:1, 2:1:1, 2:2:1 и 1:1:1.
6. Композиция для применения по любому из пп. 1-5, дополнительно содержащая штамм бактерий, принадлежащих виду Streptococcus thermophilus, идентифицированный как Streptococcus thermophilus ST10 DSM 25246, и камедь тары, где указанный штамм при введении способен продуцировать экзополисахариды in situ.
7. Композиция для применения по любому из пп. 1-6, дополнительно содержащая камедь, предпочтительно альгинат или его производное, еще более предпочтительно альгинат натрия.
8. Композиция для применения по любому из пп. 1-7, дополнительно содержащая гель Aloe или его производное, предпочтительно гель Aloe arborescens, причем еще более предпочтительно гель представляет собой лиофилизированный гель Aloe arborescens.
9. Композиция для применения по любому из пп. 1-8, дополнительно содержащая штамм бактерий, принадлежащих виду Bifidobacterium lactic, идентифицированный как Bifidobacterium lactic Bb 1, с депозитарным номером DSM 17850, депонированный в DSMZ 23.12.2005 BioMan S.r.l. Company, где указанный штамм обладает способностью аккумулировать цинк внутри клетки во время его роста в жидкой культуральной среде.
10. Композиция для применения по любому из пп. 1-9, используемая для защиты слизистых желудка, пищевода и кишечника у индивидуумов, проходящих противоопухолевое химиотерапевтическое лечение, лечение синдрома приобретенного иммунодефицита и лечение лейкозов.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20140815 | 2014-05-05 | ||
ITMI2014A000815 | 2014-05-05 | ||
PCT/IB2015/000614 WO2015170159A1 (en) | 2014-05-05 | 2015-04-30 | A composition for use in treating or preventing viral or bacterial infections in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy comprising l. reuteri ler03 and/or l. salivarius ls06. |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016143921A true RU2016143921A (ru) | 2018-06-05 |
RU2016143921A3 RU2016143921A3 (ru) | 2018-12-18 |
RU2713414C2 RU2713414C2 (ru) | 2020-02-05 |
Family
ID=51136601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016143921A RU2713414C2 (ru) | 2014-05-05 | 2015-04-30 | Композиция для применения в лечении или предупреждении вирусных или бактериальных инфекций у субъекта, проходящего противоопухолевую химиотерапию, лечение лейкоза или лечение СПИД, содержащая l.reuteri ler03 и/или l.salivarius ls06 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11077153B2 (ru) |
EP (1) | EP3145518B1 (ru) |
JP (2) | JP6817070B2 (ru) |
KR (1) | KR20160144501A (ru) |
CN (2) | CN111789871A (ru) |
BR (1) | BR112016024860A2 (ru) |
CA (1) | CA2946464A1 (ru) |
RU (1) | RU2713414C2 (ru) |
WO (1) | WO2015170159A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2946464A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Adjunctive therapy to chemotherapy treatments for tumors, acquired immunodeficiency syndrome and leukemias |
WO2015170158A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
ITUB20155700A1 (it) * | 2015-11-18 | 2017-05-18 | Probiotical Spa | Composizioni con azione sinergica tra un complesso gelificante muco-aderente contro il passaggio degli antigeni, e batteri immunomodulanti anti-IL17 per uso nel trattamento delle malattie autoimmuni e neurodegenerative IL17 dipendenti. |
IT201700068009A1 (it) * | 2017-06-19 | 2018-12-19 | Probiotical Spa | Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson |
IT201700093527A1 (it) * | 2017-08-11 | 2019-02-11 | Probiotical Spa | Composizione a base di ceppi di batteri e/o loro derivati per la stimolazione del sistema immunitario per via topica o sistemica per il trattamento di infezioni virali come il Papilloma virus |
DE202020104290U1 (de) * | 2019-07-24 | 2020-11-25 | Syngen Biotech Co.,Ltd. | Zusammensetzung aus Streptococcus Thermophilus vom Stamm ST4 als ein Hilfsstoff eines Chemotherapeutikums zur Besserung von Diarrhoe, Appetitstörungen und zur Gewichtserhaltung |
KR102273663B1 (ko) * | 2020-10-29 | 2021-07-05 | 주식회사 에치와이 | 코팅 프로바이오틱스 및 이를 포함하는 식품 조성물, 이의 제조방법 |
CN113215063B (zh) * | 2021-06-16 | 2023-02-21 | 中国药科大学 | 一种唾液乳杆菌及其应用 |
CN115181682B (zh) * | 2022-02-10 | 2023-10-03 | 江南大学 | 一株高富集有机锌的发酵乳杆菌 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0814822B1 (en) * | 1995-12-21 | 2003-05-07 | BioGaia AB | Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals |
CN1370587A (zh) | 2002-03-05 | 2002-09-25 | 王舒妍 | 芦荟凝胶的制备方法 |
BR0215884A (pt) | 2002-10-18 | 2005-12-20 | Biogaia Ab | Método para melhorar a função imunológica em mamìferos usando cepas de lactobacillus reuteri |
ITMI20051510A1 (it) | 2005-08-02 | 2007-02-03 | Proge Farm Srl | Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti |
JP2007084533A (ja) * | 2005-08-24 | 2007-04-05 | Prima Meat Packers Ltd | 免疫応答調節組成物及び該組成物を有効成分とする食品 |
JP4864787B2 (ja) | 2007-03-28 | 2012-02-01 | 株式会社日立製作所 | 粒子線照射システムおよびその制御方法 |
ITTO20070555A1 (it) | 2007-07-26 | 2009-01-27 | Bioman S R L | Biomassa arricchita in zinco, procedimento per la sua preparazione e prodotti probiotici, cosmetici, dietetici e nutraceutici comprendenti tale biomassa |
CN101249109B (zh) * | 2008-03-14 | 2012-06-27 | 华侨大学 | 罗伊氏乳杆菌益生中空微胶囊的制备方法 |
TWI346554B (en) | 2008-04-30 | 2011-08-11 | Genmont Biotech Inc | Lactobacillus isolates having anti-inflammatory activities and uses of the same |
KR101001767B1 (ko) | 2008-11-04 | 2010-12-15 | 주식회사한국야쿠르트 | 항 인플루엔자 바이러스 효능을 갖는 락토바실러스 루테리 에이취와이7501 및 이를 유효성분으로 함유하는 제품 |
US20100143305A1 (en) * | 2008-12-08 | 2010-06-10 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
US20110117210A1 (en) | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
CN101974463B (zh) * | 2010-10-19 | 2012-05-09 | 黑龙江八一农垦大学 | 罗伊氏乳杆菌及其复合活菌制剂 |
US20120107395A1 (en) | 2010-11-01 | 2012-05-03 | Viva Pharmaceutical Inc. | Probiotic Soft Gel Compositions |
CN102618452B (zh) | 2011-02-01 | 2014-06-25 | 任发政 | 唾液乳杆菌及其代谢物的制备方法和组合物以及应用 |
JP5784327B2 (ja) * | 2011-02-28 | 2015-09-24 | 森永乳業株式会社 | 抗菌剤 |
ITMI20110679A1 (it) | 2011-04-20 | 2012-10-21 | Giovanni Mogna | Composizione comprendente batteri probiotici in grado di ripristinare l effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell iperacidita gastrica. |
ITRM20110477A1 (it) * | 2011-09-09 | 2013-03-10 | Giovanni Mogna | Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell |
KR20130048946A (ko) | 2011-11-03 | 2013-05-13 | 가톨릭대학교 산학협력단 | 락토바실러스 루테리 cs132 또는 이의 배양물을 포함하는 항암용 조성물 |
ITMI20112238A1 (it) | 2011-12-09 | 2013-06-10 | Probiotical Spa | Ceppi di batteri probiotici produttori di vitamina b12 |
ITMI20120131A1 (it) | 2012-02-01 | 2013-08-02 | Probiotical Spa | Batteri probiotici microincapsulati multistrato, loro produzione ed uso |
ITMI20121328A1 (it) * | 2012-07-30 | 2014-01-31 | Probiotical Spa | Composizione per dispositivo medico comprendente ceppi di batteri produttori di esopolisaccaridi in associazione con gomme e/o gelatine. |
WO2015170158A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
CA2946464A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Adjunctive therapy to chemotherapy treatments for tumors, acquired immunodeficiency syndrome and leukemias |
-
2015
- 2015-04-30 CA CA2946464A patent/CA2946464A1/en not_active Abandoned
- 2015-04-30 US US15/307,757 patent/US11077153B2/en active Active
- 2015-04-30 BR BR112016024860A patent/BR112016024860A2/pt not_active Application Discontinuation
- 2015-04-30 RU RU2016143921A patent/RU2713414C2/ru active
- 2015-04-30 CN CN202010065424.1A patent/CN111789871A/zh active Pending
- 2015-04-30 CN CN201580024004.6A patent/CN106573022A/zh active Pending
- 2015-04-30 WO PCT/IB2015/000614 patent/WO2015170159A1/en active Application Filing
- 2015-04-30 JP JP2016566716A patent/JP6817070B2/ja active Active
- 2015-04-30 EP EP15726675.0A patent/EP3145518B1/en active Active
- 2015-04-30 KR KR1020167033184A patent/KR20160144501A/ko not_active Application Discontinuation
-
2020
- 2020-08-07 JP JP2020135085A patent/JP2020193207A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20170112883A1 (en) | 2017-04-27 |
US11077153B2 (en) | 2021-08-03 |
EP3145518A1 (en) | 2017-03-29 |
JP2020193207A (ja) | 2020-12-03 |
RU2713414C2 (ru) | 2020-02-05 |
JP6817070B2 (ja) | 2021-01-20 |
RU2016143921A3 (ru) | 2018-12-18 |
JP2017514862A (ja) | 2017-06-08 |
EP3145518B1 (en) | 2021-02-17 |
BR112016024860A2 (pt) | 2017-10-17 |
CA2946464A1 (en) | 2015-11-12 |
CN111789871A (zh) | 2020-10-20 |
KR20160144501A (ko) | 2016-12-16 |
WO2015170159A1 (en) | 2015-11-12 |
CN106573022A (zh) | 2017-04-19 |
WO2015170159A8 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016143921A (ru) | Композиция для применения в лечении или предупреждении вирусных или бактериальных инфекций у субъекта, проходящего противоопухолевую химиотерапию, лечение лейкоза или лечение СПИД, содержащая l.reuteri ler03 и/или l.salivarius ls06 | |
Reuben et al. | Characterization and evaluation of lactic acid bacteria from indigenous raw milk for potential probiotic properties | |
JP2015213501A5 (ru) | ||
Wan et al. | In vitro evaluation of swine-derived Lactobacillus reuteri: probiotic properties and effects on intestinal porcine epithelial cells challenged with enterotoxigenic Escherichia coli K88 | |
Manzoor et al. | Efficacy of locally isolated lactic acid bacteria against antibiotic-resistant uropathogens | |
Mirzaei et al. | Antimicrobial properties of lactic acid bacteria isolated from traditional yogurt and milk against Shigella strains | |
Jomehzadeh et al. | Isolation and identification of potential probiotic Lactobacillus species from feces of infants in southwest Iran | |
Rajkowska et al. | Probiotic activity of Saccharomyces cerevisiae var. boulardii against human pathogens | |
EP4272815A3 (en) | New medical use of probiotics | |
Koll et al. | Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics | |
CN103642716A (zh) | 一种植物乳杆菌及其应用 | |
Han et al. | Antibiotic susceptibility of potentially probiotic Lactobacillus strains | |
RU2016143922A (ru) | Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции | |
Bolla et al. | Kefir-isolated bacteria and yeasts inhibit Shigella flexneri invasion and modulate pro-inflammatory response on intestinal epithelial cells | |
MX2012011706A (es) | Uso de streptococcus salivarius en el tratamiento de infecciones cronicas del tracto respiratorio. | |
Wu et al. | Evaluation of the Probiotic Potential of ssp. WDS-7 Isolated from Chinese Traditional Fermented Buffalo Milk | |
Huang et al. | Characterization of high exopolysaccharide-producing Lactobacillus strains isolated from mustard pickles for potential probiotic applications | |
Lim | Anti-Helicobacter pylori activity of antimicrobial substances produced by lactic acid bacteria isolated from Baikkimchi | |
Skrzypczak et al. | Health-promoting properties exhibited by Lactobacillus helveticus strains | |
Bahri et al. | Characterization of Lactobacillus strains isolated from Algerian children faeces for their probiotic properties | |
Mändar et al. | Antibacterial susceptibility of intestinal lactobacilli of healthy children | |
Zangeneh et al. | Isolation of Lactobacillus plantarum strains with robust antagonistic activity, qualified probiotic properties, and without antibiotic-resistance from traditional sourdough | |
RU2015124336A (ru) | Композиция для применения в качестве поддерживающей терапии при лечении опухолей, синдрома приобретенного иммунодефицита и лейкемии | |
Xing et al. | Enhancing the culturability of bacteria from the gastrointestinal tract of farmed adult turbot Scophthalmus maximus | |
Chakoosari et al. | Antimicrobial Effect of Lactic Acid Bacteria against Common Pathogenic Bacteria. |